NCT02720224View on ClinicalTrials.gov

Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
ContraceptionMenopause
Interventions
DRUG

Estetrol

15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

Sponsors

Lead Sponsor

Estetra

Collaborators (1)

Quotient Clinical
All Listed Sponsors
collaborator

Quotient Clinical

OTHER

lead

Estetra

INDUSTRY

NCT02720224 - Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol | Biotech Hunter | Biotech Hunter